Cargando…

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study

BACKGROUND/AIMS: The safety and effectiveness of adalimumab was demonstrated in a phase 3 trial in Japanese patients with intestinal Behçet’s disease. The aim of this study was to evaluate the long-term safety and effectiveness of adalimumab in Japanese patients with intestinal Behçet’s disease. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Yasuo, Hagiwara, Takashi, Kobayashi, Mariko, Morita, Kazuo, Shimamoto, Tomoyo, Hibi, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322033/ https://www.ncbi.nlm.nih.gov/pubmed/32814420 http://dx.doi.org/10.5217/ir.2020.00013

Ejemplares similares

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
por: Hisamatsu, Tadakazu, et al.
Publicado: (2021)

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
por: Ogata, Haruhiko, et al.
Publicado: (2021)

Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease
por: Kaji, Mariko, et al.
Publicado: (2015)

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
por: Inoue, Nagamu, et al.
Publicado: (2017)

Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
por: Lee, Seung Bum, et al.
Publicado: (2023)

Adalimumab in the management of Behçet’s disease
por: Ueda, Atsuhisa, et al.
Publicado: (2015)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

Behçet's disease-induced massive small intestinal bleeding successfully treated with adalimumab
por: Liu, PH, et al.
Publicado: (2023)

Pulmonary Sarcoidosis in Behçet’s Disease Treated with Adalimumab
por: Louro, Marlene, et al.
Publicado: (2017)

Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
por: Park, Jihye, et al.
Publicado: (2017)

Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome
por: Kimura, Masamichi, et al.
Publicado: (2015)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Early administration of adalimumab for paediatric uveitis due to Behçet’s disease
por: Hiyama, Tomona, et al.
Publicado: (2019)

The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet’s Retinal Vasculitis
por: Yang, Shizhao, et al.
Publicado: (2021)

Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab: A case report
por: Yan, Zhe, et al.
Publicado: (2019)

Serum KL-6 elevation in a uveitis patient with Behçet's disease treated with adalimumab
por: Ono, Takashi, et al.
Publicado: (2020)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Adalimumab in Treatment of Uveitis in Pediatric Behcet’s Disease–a Case Report
por: Halilbasic, Meliha, et al.
Publicado: (2021)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies
por: Hisamatsu, Tadakazu, et al.
Publicado: (2013)

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet’s Syndrome
por: Sota, Jurgen, et al.
Publicado: (2021)

Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
por: Tang Lee Say, Timothy Lee, et al.
Publicado: (2021)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
por: Saal, Ryan C., et al.
Publicado: (2023)

Nationwide real-world database of 20,462 patients enrolled in the Japanese Acute Myocardial Infarction Registry (JAMIR): Impact of emergency coronary intervention in a super-aging population
por: Kojima, Sunao, et al.
Publicado: (2018)

Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab
por: Okabayashi, Shinji, et al.
Publicado: (2017)

Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Microsoft SQL Server 2012 administration: real-world skills for MCSA certification and beyond (exams 70-461, 70-462, and 70-463)
por: Carpenter, Tom
Publicado: (2013)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
por: Bonafede, Machaon, et al.
Publicado: (2013)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

ODP462 Amiodarone Induced Thyrotoxicosis-Treatment Challenges
por: Firak, Gabriela, et al.
Publicado: (2022)

Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis
por: Ho, Mary, et al.
Publicado: (2019)

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
por: Hibi, Toshifumi, et al.
Publicado: (2016)

Intestinal Perforations in Behçet’s Disease
por: Chou, Shao-Jiun, et al.
Publicado: (2007)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data
por: Marquez-Megias, Silvia, et al.
Publicado: (2023)

Impact of inflammatory bowel disease on Japanese patients’ quality of life: results of a patient questionnaire survey
por: Ueno, Fumiaki, et al.
Publicado: (2016)

SAT462 TSI Versus TRAb In The Diagnosis Of Grave’s Disease
por: Ibrahim, Katherine, et al.
Publicado: (2023)

A new start for 'Intestinal Research' as an official journal of AOCC
por: Hibi, Toshifumi
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g8or8g11fcngc81dg8vojo5fej